1. Home
  2. PCRX vs MMI Comparison

PCRX vs MMI Comparison

Compare PCRX & MMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • MMI
  • Stock Information
  • Founded
  • PCRX 2006
  • MMI 1971
  • Country
  • PCRX United States
  • MMI United States
  • Employees
  • PCRX N/A
  • MMI N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • MMI Real Estate
  • Sector
  • PCRX Health Care
  • MMI Finance
  • Exchange
  • PCRX Nasdaq
  • MMI Nasdaq
  • Market Cap
  • PCRX 1.2B
  • MMI 1.2B
  • IPO Year
  • PCRX 2011
  • MMI 2013
  • Fundamental
  • Price
  • PCRX $26.86
  • MMI $32.16
  • Analyst Decision
  • PCRX Buy
  • MMI Sell
  • Analyst Count
  • PCRX 6
  • MMI 2
  • Target Price
  • PCRX $30.00
  • MMI $30.00
  • AVG Volume (30 Days)
  • PCRX 592.7K
  • MMI 109.8K
  • Earning Date
  • PCRX 11-05-2025
  • MMI 11-07-2025
  • Dividend Yield
  • PCRX N/A
  • MMI 1.55%
  • EPS Growth
  • PCRX N/A
  • MMI N/A
  • EPS
  • PCRX N/A
  • MMI N/A
  • Revenue
  • PCRX $705,848,000.00
  • MMI $725,903,000.00
  • Revenue This Year
  • PCRX $7.36
  • MMI $9.50
  • Revenue Next Year
  • PCRX $10.07
  • MMI $17.73
  • P/E Ratio
  • PCRX N/A
  • MMI N/A
  • Revenue Growth
  • PCRX 2.25
  • MMI 17.89
  • 52 Week Low
  • PCRX $13.04
  • MMI $27.61
  • 52 Week High
  • PCRX $27.64
  • MMI $42.80
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 61.04
  • MMI 51.23
  • Support Level
  • PCRX $25.63
  • MMI $32.10
  • Resistance Level
  • PCRX $27.11
  • MMI $33.31
  • Average True Range (ATR)
  • PCRX 0.96
  • MMI 0.69
  • MACD
  • PCRX -0.05
  • MMI -0.03
  • Stochastic Oscillator
  • PCRX 68.80
  • MMI 33.64

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About MMI Marcus & Millichap Inc.

Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.

Share on Social Networks: